
|Articles|February 18, 2004
Investigational PDE-5 inhibitor comparable to sildenafil, study shows
A phase II study comparing the onset of action of two oral phosphodiesterase-type 5 inhibitors?TA-1790, an investigational agent and sildenafil citrate (Viagra) showed comparable results, according to VIVUS, Inc., maker of TA-1790.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study launches of MRI plus PSMA-PET imaging for prostate cancer detection
2
Initial ARID results published in World Journal of Urology as pivotal trial progresses
3
New Data Influencing your Treatment Decisions in mCSPC
4
Wesley Chou, MD, shares early insights into gene expression changes in treated RCC
5



















